A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cephalalgia

• Publication date

  2017-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0333102416637833PMID 26951335
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CGRP Mechanism Antagonists and Migraine Management

  2015cited by this paper
• Reduced trigeminovascular cyclicity in patients with menstrually related migraine

  2015cited by this paper
• Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead

  2014cited by this paper
• Triptan nonresponders: Do they exist and who are they?

  2013cited by this paper
• Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience

  2013cited by this paper
• Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.

  2013cited by this paper
• Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.

  2011cited by this paper
• Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs

  2011cited by this paper
• Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

  2010cited by this paper
• Coronary side-effect potential of current and prospective antimigraine drugs.

  1998cited by this paper
• Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.

  1994cited by this paper
• The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats

  1993cited by this paper

• Neurophysiological and Vascular Mechanisms of Action of Serotoninergic Drugs for Abortive Migraine Treatment

  2024cites this paper
• Understanding the Biological Relationship between Migraine and Depression

  2024cites this paper
• Neurophysiological and Vascular Mechanisms of Action of the Serotoninergic Drugs for Abortive Migraine Treatment

  2023cites this paper
• Serotonergic Modulation of Neurovascular Transmission: A Focus on Prejunctional 5-HT Receptors/Mechanisms

  2023cites this paper
• Pediatric Migraines: A Comprehensive Review and Perspectives on Diagnosis and Treatment

  2023cites this paper
• Trigeminovascular effects of propranolol in men and women, role for sex steroids

  2022cites this paper
• Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine

  2021cites this paper
• Evaluating rimegepant for the treatment of migraine

  2021cites this paper
• Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine.

  2021cites this paper
• A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches

  2020cites this paper
• Targeting CGRP and 5‐HT1F Receptors for the Acute Therapy of Migraine: A Literature Review

  2019cites this paper
• Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?

  2018cites this paper
• Current understanding of meningeal and cerebral vascular function underlying migraine headache

  2018cites this paper
• Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration

  2018cites this paper
• Triptans and CGRP blockade – impact on the cranial vasculature

  2017cites this paper
• Genetic and biochemical changes of the serotonergic system in migraine pathobiology

  2017cites this paper